Psychedelics elicit their effects by 5-HT2A receptor-mediated Gi signalling

Psychedelics elicit their effects by 5-HT2A receptor-mediated Gi signalling

Psychedelics are undergoing a renaissance as potential therapy for psychiatric disorders, with more than 200 clinical trials being studied across several countries1–3. However, the precise mechanisms by which these drugs bring about benefits and the potential clinical risks are not yet fully understood. The serotonin 2A receptor (5-HT2AR) was reported to be a Gq-coupled receptor and the primary interoceptive target of psychedelics4,5. Here we co…